-
Mashup Score: 0Unlocking cancer biomarkers with AI - 2 year(s) ago
Revitalizing the cancer therapeutics industry – 90% of clinical trials fail, with the average trial costing $793M. Despite its $100K/year price, immunotherapy is only partially effective in 17% of patients.
Source: key.bioCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
A single-institution study revealed that 37% of patients who underwent radical cystectomy experienced at least 1 additional intervention.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A single-institution study revealed that 37% of patients who underwent radical cystectomy experienced at least 1 additional intervention.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Study shows value of radical cystectomy–pentafecta for measuring quality of RARC surgery - 3 year(s) ago
Patients achieving RC-pentafecta had less blood loss, shorter hospital stays, and lower perioperative mortality.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort - 3 year(s) ago
Radical cystectomy (RC) has the potential for profound changes to health-related quality of life (HRQOL).To evaluate a broad range of HRQOL outcomes i…
Source: www.sciencedirect.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Refining Neoadjuvant Therapy Clinical Trial Design for Muscle-Invasive Bladder Cancer Before Cystectomy - 3 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Selecting the Appropriate Patient for Timely Cystectomy for Non–Muscle Invasive Bladder Cancer - 4 year(s) ago
Written by Anirban P. Mitra MD, PhD Written by Colin P. N. Dinney MD Written by Tanner Miest MD, PhD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Outcomes Associated With Variant Histology Bladder Cancers Managed by Cystectomy With or Without Neoadjuvant Chemotherapy - 4 year(s) ago
Written by Brant A. Inman MD, MS
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder - 4 year(s) ago
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Written by Anirban P. Mitra MD, PhD Written by Colin P N Dinney MD Written by Tanner Miest MD, PhD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
Neural network analysis of germline+tumor molecular alterations shows large impact of host to predict 5-yr survival with high accuracy post-#radicalcystectomy for muscle-invasive #bladdercancer @LayneSadler https://t.co/meEm1f6TxI https://t.co/6VnqZ9fTCz @onclive